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During the course of experimental work on acquired hypotrichosis and canities, it was
noted that in discoid lupus erythematosus of the scalp there was improvement of the in-
flammatory phase of the disease associated with calcium pantothenate therapy. Following
this, a series of patients with subacute and localized and disseminated discoid lupus cry-
thematosus was studied with oral calcium pantothenate. The dosage originally was 200—
250 mgs., but at present 400 mgs. are given daily. No additional therapy was used except
a bland covering paste. Several of the patients had prior therapy with sodium paramino-
benzoate (Na-PAB). In some instances calcium pantothenate therapy was discontinued
deliberately for periods of 4 to 6 weeks in order to determine the effect of omission of
therapy. In two of the patients calcium lactate was substituted for calcium pantothenate
therapy without response. To date, 14 patients have been treated. There were no reac-
tions to the therapy, unlike the newer chemotherapeutic agents, including Na-PAB (hema-
topoetic changes), used in the therapy of lupus erythematosus. As might be expected the
subacute types showed the most marked response. Three cases of the discoid type required
phenol cauterization of the active border. Only one patient of the discoid group developed
new lesions under therapy.
No intravenous calcium pantothenate therapy was used. No cases of active acute dis-
seminated forms were treated in the present series. Treatment of this group will be de-
ferred until a more detailed picture of intensive calcium pantothenate can be obtained.
The capriciousness of the response to therapy of discoid lupus erythematosus is well known
and should be considered in the critical evaluation of any new therapeutic agent offered.
CONCLUSIONS
Preliminary results in individuals with subacute and localized and disseminated discoid
lupus erythematosus showed significant improvement under massive calcium pantothenate
therapy. Further trials with this seem indicated since this agent is perhaps the most
innocuous of the chemotherapeutic agents suggested for prolonged therapy in this disease.
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